Phase 3 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older (there is no upper age limit for the general trial)
- People who have a history of a type of irregular heartbeat called atrial fibrillation (paroxysmal, persistent, or long-standing), confirmed by a heart tracing (ECG)
- People whose atrial fibrillation-related stroke risk score (called CHA2DS2VASc) is 2 or higher, meaning long-term blood thinning treatment has been recommended for them
- People who have had a bleed inside the brain (intracerebral haemorrhage) — whether or not they were on blood thinners at the time — confirmed by a brain scan (CT or MRI)
- People whose brain bleed occurred more than 14 days before joining the trial (there is no maximum time limit after the bleed)
- People where there is genuine uncertainty among their medical team about the best approach to prevent future strokes or vascular events
Who may not be able to join:
- People who have significant disability before joining the trial, rated 4 or 5 on a standard disability scale (the modified Rankin Scale)
- People who need long-term blood thinners for a reason other than atrial fibrillation, such as having a mechanical heart valve
- People who have had a serious bleeding event (other than a brain bleed) in the 6 months before joining the trial
- People whose life expectancy is less than 1 year
- People who are pregnant or breastfeeding
- People being considered for the heart procedure arm of the trial (called Left Atrial Appendage Closure, or LAAC) who have certain physical or anatomical reasons that make the procedure unsuitable, such as a blood clot in a specific part of the heart, or a current infection risk (confirm with trial site)
- People being considered for the LAAC procedure arm who are older than 85 years
- People being considered for the LAAC procedure arm whose stroke risk score (CHA2DS2VASc) is only 2 or 3
- People being considered for the LAAC procedure arm where either the patient or their doctor is unwilling to proceed with that procedure
- People being considered for the blood-thinning medication arm who have severe kidney problems (confirm with trial site for specific test values)
- People being considered for the blood-thinning medication arm who weigh less than 50 kg
- People being considered for the blood-thinning medication arm who have an allergy to the medication apixaban
- People being considered for the blood-thinning medication arm who have conditions that make falls or head injuries more likely, such as balance problems or uncontrolled seizures
- People being considered for the blood-thinning medication arm where either the patient or their doctor is unwilling to use that type of medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charlotte Cordonnier, MD, PhD, University Hospital Lille, Inserm, Univ Lille
Phone: 3 20 44 68 14
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite of all fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.